Clinical Trial

Visual Changes and Retinal Vein Occlusion and Macular Edema

Study Description

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion

The purpose of this study is to evaluate the efficacy and safety of brolucizumab in treatment of patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO).

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - Brolucizumab 6 mg

Solution for injection (intravitreal use)

Drug - Aflibercept 2 mg

Solution for injection (Intravitreal use)

Sham injection

Empty sterile syringe without a needle administered as a sham injection for masking

Additional Information

Official Study Title

An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion

Clinical Trial ID

NCT03810313

ParticipAid ID

e5yVZe